Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

IGF-I in the clinics : Use in retinopathy of prematurity

Hellström, Ann ; Ley, David LU ; Hansen-Pupp, Ingrid LU orcid ; Hallberg, Boubou ; Ramenghi, Luca A. ; Löfqvist, Chatarina ; Smith, Lois E H and Hård, Anna Lena (2016) In Growth Hormone and IGF Research 30-31. p.75-80
Abstract

Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23. weeks+0. days and 27. weeks +. 6. days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia... (More)

Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23. weeks+0. days and 27. weeks +. 6. days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Fetus, IGF-I, Metabolism, Postnatal growth, Preterm infant, Preterm morbidity
in
Growth Hormone and IGF Research
volume
30-31
pages
75 - 80
publisher
Elsevier
external identifiers
  • scopus:84992058856
  • pmid:27720550
  • wos:000390724400013
ISSN
1096-6374
DOI
10.1016/j.ghir.2016.09.005
language
English
LU publication?
yes
id
478602e2-b0a4-41b9-99da-6151a879a93e
date added to LUP
2016-11-04 10:46:30
date last changed
2025-10-14 12:42:24
@article{478602e2-b0a4-41b9-99da-6151a879a93e,
  abstract     = {{<p>Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23. weeks+0. days and 27. weeks +. 6. days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.</p>}},
  author       = {{Hellström, Ann and Ley, David and Hansen-Pupp, Ingrid and Hallberg, Boubou and Ramenghi, Luca A. and Löfqvist, Chatarina and Smith, Lois E H and Hård, Anna Lena}},
  issn         = {{1096-6374}},
  keywords     = {{Fetus; IGF-I; Metabolism; Postnatal growth; Preterm infant; Preterm morbidity}},
  language     = {{eng}},
  month        = {{08}},
  pages        = {{75--80}},
  publisher    = {{Elsevier}},
  series       = {{Growth Hormone and IGF Research}},
  title        = {{IGF-I in the clinics : Use in retinopathy of prematurity}},
  url          = {{http://dx.doi.org/10.1016/j.ghir.2016.09.005}},
  doi          = {{10.1016/j.ghir.2016.09.005}},
  volume       = {{30-31}},
  year         = {{2016}},
}